A composition comprising a non-covalent complex of a donor oligonucleotide comprising a sequence that can correct a mutation(s) in a cell's genome, and a potentiating agent that engages one or more DNA repair pathways and increases genomic editing by the donor oligonucleotide compared to the donor alone, wherein the potentiating agent is a cell-penetrating monoclonal antibody or a cell-penetrating fragment thereof; a cell-penetrating monovalent, divalent, or multivalent single chain variable fragment (scFv); or a cell-penetrating diabody; or a cell-penetrating humanized form or variant, wherein the cell-penetrating monoclonal antibody or the cell-penetrating fragment thereof; the cell-penetrating monovalent, divalent, or multivalent single chain variable fragment (scFv); or the cell-penetrating diabody; or the cell-penetrating humanized form or variant comprises: (a) a heavy chain variable region (V H) complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 15, (b) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 17, (c) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 18, (d) a light chain variable region (V L) CDR1 comprising the amino acid sequence of SEQ ID NO: 24, (e) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (f) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 26; or (a) a heavy chain variable region (V H) complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 16, (b) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 17, (c) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 18, (d) a light chain variable region (V L) CDR1 comprising the amino acid sequence of SEQ ID NO: 24, (e) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (f) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 26. a donor oligonucleotide comprising a sequence that can correct a mutation(s) in a cell's genome, and a potentiating agent that engages one or more DNA repair pathways and increases genomic editing by the donor oligonucleotide compared to the donor alone, wherein the potentiating agent is a cell-penetrating monoclonal antibody or a cell-penetrating fragment thereof; a cell-penetrating monovalent, divalent, or multivalent single chain variable fragment (scFv); or a cell-penetrating diabody; or a cell-penetrating humanized form or variant, wherein the cell-penetrating monoclonal antibody or the cell-penetrating fragment thereof; the cell-penetrating monovalent, divalent, or multivalent single chain variable fragment (scFv); or the cell-penetrating diabody; or the cell-penetrating humanized form or variant comprises: (a) a heavy chain variable region (V H) complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 15, (b) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 17, (c) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 18, (d) a light chain variable region (V L) CDR1 comprising the amino acid sequence of SEQ ID NO: 24, (e) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (f) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 26; or (a) a heavy chain variable region (V H) complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 16, (b) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 17, (c) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 18, (d) a light chain variable region (V L) CDR1 comprising the amino acid sequence of SEQ ID NO: 24, (e) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (f) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 26. (a) a heavy chain variable region (V H) complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 15, (b) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 17, (c) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 18, (d) a light chain variable region (V L) CDR1 comprising the amino acid sequence of SEQ ID NO: 24, (e) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (f) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 26; or (a) a heavy chain variable region (V H) complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 16, (b) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 17, (c) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 18, (d) a light chain variable region (V L) CDR1 comprising the amino acid sequence of SEQ ID NO: 24, (e) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (f) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 26.